Skip to main content
SpringerLink
Log in
Book cover

Drugs for the Treatment of Parkinson’s Disease pp 459–470Cite as

Pergolide in the Treatment of Parkinson’s Disease

  • Chapter

  • 325 Accesses

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 88))

Abstract

Pergolide mesylate, a synthetic semiergoline, is a potent dopamine agonist which holds promise as a treatment for Parkinson’s disease. Its chemical name is (8 β)-8-[(methylthio)methyl]-6-propylergoline monomethanesulfonate; its empirical formula is C20H30N2O3S2 (Fig. 1), and its molecular weight is 410.6.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in parkinsonism. Br Med J [Clin Res] 4: 442–444

    Article  CAS  Google Scholar 

  • Clemens JA, Smalstig EB (1979) Effects of some new dopamine agonists on turning behavior in 6-hydroxydopamine lesioned rats. IRCS Med Sci 6: 427

    Google Scholar 

  • Diamond SG, Markham CH (1984) One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson’s disease. In: Hassler RG, Christ JF (eds) Advances in neurology. Raven, New York, pp 537–539

    Google Scholar 

  • Diamond SG, Markham CH, Treciokas LJ (1985) Double-blind trial of pergolide for Parkinson’s disease, Neurology 35: 291–295

    PubMed  CAS  Google Scholar 

  • Goetz CG, Tanner CM, Glantz RH, Klawans HL (1985) Chronic agonist therapy for Parkinson’s disease: a 5-year study of bromocriptine and pergolide. Neurology 35: 749–751

    PubMed  CAS  Google Scholar 

  • Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH (1980) Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 77: 3725–3728

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology (Minneapolis) 17: 427–442

    CAS  Google Scholar 

  • Hoehn MM, Schear MJ, Heaton A (1985) Comparison of pergolide, bromocriptine, and mesulergine in the management of complications of levodopa therapy. Neurology 35 (Suppl 1): 202

    Google Scholar 

  • Horowski R (1978) Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and D-LSD as compared with apomorphine. Eur J Pharmacol 51: 157–166

    Article  PubMed  CAS  Google Scholar 

  • Hurtig HI, Saykin A, Stern MB, Melvin G, Cline S, Fuller J, Gur R (1985) Pergolide improves motor function in Parkinson’s disease without causing adverse mental effects: a neuropsychological study. Neurology 35 (Suppl 1): 202

    Google Scholar 

  • Ilson J, Fahn S, Mayeux R, Cote LJ (1982) Pergolide treatment in parkinsonism. Neurology 32 (2): 181

    Google Scholar 

  • Ilson J, Fahn S, Mayeux R, Cote LJ, Snider SR (1983) Pergolide treatment in parkinsonism. In: Fahn S, Calne DB, Shoulson I (eds) Experimental therapeutics of movement disorders, Vol 37. Raven, New York, pp 85–94

    Google Scholar 

  • Jankovic J (1985) Long-term study of pergolide in Parkinson’s disease. Neurology 35: 296–299

    PubMed  CAS  Google Scholar 

  • Jiang DH, Reches A, Wagner HR, Fahn S (1984) Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain. Neuropharmacology 23: 295–301

    Article  PubMed  CAS  Google Scholar 

  • Kleinberg DL, Lieberman A, Todd J, Greising J, Neophytides A, Kupersmith M (1980) Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys, and patients with Parkinson’s disease. J Clin Endocrinol Metab 51: 152–154

    Article  PubMed  CAS  Google Scholar 

  • Kurland R, Miller C, Levy R, Macik B, Hamill R, Shoulson I (1985) Long-term experience with pergolide therapy of advanced parkinsonism. Neurology 35: 738–742

    Google Scholar 

  • Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD (1982) Pergolide in late-stage Parkinson disease. Ann Neurol 12: 243–247

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ, Stern GM (1981) Pergolide and lisuride for levodopa-induced oscillations. Lancet 2: 577

    Article  PubMed  CAS  Google Scholar 

  • Leibowitz M, Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Gopinathan G, Mehl S (1981) Cardiac effects of pergolide. Clin Pharmacol Ther 30: 718–723

    Article  PubMed  CAS  Google Scholar 

  • Lemberger L, Crabtree RE (1979) Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science 205: 1151–1153

    Article  PubMed  CAS  Google Scholar 

  • LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster N, Dambrosia JM, Calne DB (1983) Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 33: 1009–1014

    PubMed  CAS  Google Scholar 

  • Lieberman AN, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D (1981) Treatment of advanced Parkinson disease with pergolide. Neurology 31: 675–682

    PubMed  CAS  Google Scholar 

  • Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesiger E, Nelson J (1982) Further studies with pergolide in Parkinson disease. Neurology 32: 1181–1184

    PubMed  CAS  Google Scholar 

  • Lieberman AN, Goldstein M, Leibowitz M, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R (1984) Long-term treatment with pergolide: decreased efficacy with time. Neurology 34: 223–226

    PubMed  CAS  Google Scholar 

  • Lieberman AN, Leibowitz M, Gopinathan G, Walker R, Hiesiger E, Nelson J, Goldstein M (1985) Review: the use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease. Am J Med Sci 290: 102–106

    Article  PubMed  CAS  Google Scholar 

  • Lieberman AN, Gopinathan G, Neophytides A (1986) Efficacy of pergolide and mesulergine. Eur Neurol 25: 86–90

    Article  PubMed  CAS  Google Scholar 

  • Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson disease. Neurology 31: 125–131

    PubMed  CAS  Google Scholar 

  • Markham CH, Diamond SG (1986 a) Modification of Parkinson’s disease by long-term levodopa. Arch Neurol 43(4):405–407

    Google Scholar 

  • Markham CH, Diamond SG (1986b) Long-term follow up of early dopa treatment in Parkinson’s disease. Ann Neurol 19: 365–372

    Article  PubMed  CAS  Google Scholar 

  • Mear JY, Barroche G, de Smet Y, Weber M, Lhermitte F, Agid Y (1984) Pergolide in the treatment of Parkinson’s disease. Neurology 34: 983–986

    PubMed  CAS  Google Scholar 

  • Rabey JM, Passeltiner P, Markey K, Asano T, Goldstein M (1981) Stimulation of pre- and post-synaptic dopamine receptors by an ergoline and by a partial ergoline. Brain Res 225: 347–356

    Article  PubMed  CAS  Google Scholar 

  • Reavill C, Jenner P, Marsden CD (1981) Puzzles of the mechanism of action of bromocriptine. In: Gessa EL, Corsini GU (eds) Basic pharmacology, vol 1. Apomorphine and other dopaminomimetics. Raven, New York, pp 229–239

    Google Scholar 

  • Rinne UK (1981) Dopaminergic agonists in the treatment of Parkinson’s disease. Abstracts, 12th world congress of neurology, 20–25 September, Kyoto, Japan. Excerpta Medica, Amsterdam, p 133

    Google Scholar 

  • Rinne UK (1986) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease. In: Fahn S, Marsden CD, Jenner P, Teychenne P. (eds) Recent developments in Parkinson’s disease. Raven, New York, pp 267–271

    Google Scholar 

  • Roth RH (1979) Dopamine autoreceptors: pharmacology, function and comparison with postsynaptic dopamine receptors. Community Psychopharmacol 3: 429–445

    CAS  Google Scholar 

  • Sage JI, Duvoisin RC (1985 a) Long-term efficacy of pergolide in patients with Parkinson’s disease. Ann Neurol 18:137

    Google Scholar 

  • Sage JI, Duvoisin RC (1985b) Pergolide therapy in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 8(3):260–265

    Article  PubMed  CAS  Google Scholar 

  • Shoulson I, Miller C, Kurlan R, Levy R, Macik B, Hamill R (1982) Parkinsonism and on-off fluctuations: long-term effects of pergolide therapy. Ann Neurol 12: 97

    Google Scholar 

  • Stern Y, Mayeux R, Ilson J, Fahn S, Cote L (1984) Pergolide therapy for Parkinson’s disease: neurobehavioral changes. Neurology 34: 201–204

    PubMed  CAS  Google Scholar 

  • Tanner CM, Klawans HL (1982) Pergolide mesylate: new therapy for Parkinson disease. Ann Intern Med 96 (4): 522–523

    PubMed  CAS  Google Scholar 

  • Tanner CM, Goetz CG, Glantz RH, Glatt SL, Klawans HL (1982) Pergolide mesylate and idiopathic Parkinson disease. Neurology (NY) 32: 1175–1179

    CAS  Google Scholar 

  • Tanner CM, Chhablani R, Goetz CG, Klawans HL (1985) Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology 35: 918–921

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. H. Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. G. Diamond
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurology, UBC Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne Professor D.M., F.R.C.P., F.R.C.P.C. (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Markham, C.H., Diamond, S.G. (1989). Pergolide in the Treatment of Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73899-9_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73901-9

  • Online ISBN: 978-3-642-73899-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation